1600-0560/asset/olbannerleft.jpg?v=1&s=f550524ae971b4a0a06c3ec1d56b1833b462eb2d)
1600-0560/asset/olbannerright.jpg?v=1&s=3a96f574dc4e1bfda47da3c1728fe6b395cc334d)
Syringotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis
Article first published online: 9 NOV 2008
DOI: 10.1111/j.1600-0560.2008.01162.x
Copyright © 2008 John Wiley & Sons A/S
Additional Information
How to Cite
Vesel, T., Luzar, B., Calonje, E. and Avčin, T. (2009), Syringotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis. Journal of Cutaneous Pathology, 36: 991–994. doi: 10.1111/j.1600-0560.2008.01162.x
Publication History
- Issue published online: 27 JUL 2009
- Article first published online: 9 NOV 2008
- Accepted for publication August 25, 2008
- Abstract
- Article
- References
- Cited By
A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a syringotropic hypersensitivity reaction after 9 months of therapy with infliximab and leflunomide is described. Clinically, our patient showed a vasculitic-like skin rash involving both palms and soles, and histopathological examination revealed a syringotropic lymphocytic infiltrate directed toward the intra-epidermal portion of the eccrine ducts. These features have not been previously associated with infliximab or leflunomide therapy and represent a unique cutaneous hypersensitivity reaction that does not fit any known description of an immune-mediated hypersensitivity reaction.